The effects of cytokine gene transfer into tumors on host cell infiltration and regression

Anticancer Research

Volumn 16, Issue 3 A, 1996, Pages 1139-1143

  McBride, W H ^a,b   Economou, J S ^a,b   Syljuasen R G ^a   Parrish, C ^a   Hackman, D ^a   Latham, V ^a   Chiang, C S ^a   Dougherty, G J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cytokines; Gene therapy; Tumor regression

Indexed keywords

CYTOKINE;

ARTICLE; CANCER IMMUNOTHERAPY; CELL INFILTRATION; GENE THERAPY; GENE TRANSFER; HOST CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; TUMOR IMMUNITY; TUMOR REGRESSION; TUMOR REJECTION;

ANIMALS; CYTOKINES; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 0030002108     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Avalosse B, Dupont F and Burny A: Gene therapy for cancer Curr Opin Oncol 7: 94-100, 1995.
2. Bruyns C, Gerard C and Velu T: Cancer escape from immune surveillance: how can it be overcome by gene transfer? Eur J Cancer 1176- 1181,1994.
3. Dranoff G and Mulligan RC: Gene transfer as cancer therapy. Adv Immunol 58: 417-454, 1995.
4. Herrmann F: Cancer gene therapy, principles, problems, and perspectives. J Mol Med 73: 157-163,1995.
5. Miller AR, McBride WH, Hunt K and Economou JS: Cytokine-mediated gene therapy for cancer. Ann Surg Oncol 1: 436-450,1994
6. Whartenby KA, Abraham GN, Calabresi PA, Abboud CN. Calabresi P, Marrogi A and Freeman SM: Gene-modified cells for the treatment of cancer. Pharmacol Ther 66: 175-190,1995
7. Wels W, Moritz D, Schmidt M, Jeschke M, Hynes NE and Groner B: Biotechnological and gene therapeutic strategies in cancer treatment. Gene 159: 73-80,1995.
8. Edgington SM: Turning on tumor-fighting T-cells. Two signals are better than one when it come to developing new cancer therapies. Biotechnology (NY) 11. 1117-1119, 1993.
9. Pardoll DM: Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13: 399-415, 1995.
10. Chiang CS, Dougherty G, Economou JS and McBride WH: Tumordirected cytokine gene therapy. In: Gene Therapy - From Laboratory to the Clinic, (Hui K ed). Singapore, World Scientific Publishing Company, Ltd 1994, pp 20-44.
11. Hock H, Dorsch M, Kunzendorf U, Qm Z, Diamantstein T and Blankenstein T: Mechanisms of rejection induced by tumor celltargeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or Interferon gamma. Proc Natl Acad Sci USA 90: 2774-2778,1993.
12. McBride WH, Thacker JD, Comora S, Economou JS. Kelley D, Hogge D, Dubinett SM and Dougherty GJ: Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. Cancer Res 52: 3931-3937, 1992.
13. Schmidt W, Schweighoffer T, Herbst E, Maass G, Berger M, Schilcher F, Schaffner G and Birnsticl ML: Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci USA 92: 4711-4724. 1995.
14. Suit HD and Kastelan A: Immunologic status of host and response to a methyl-cholanthrene-induced fibrosarcoma to local irradiation. Cancer 26: 232-238, 1970.
15. McBride WH, Mason K. Withers HR, and Davis C. Effect of interleukin 1, inflammation, and surgery on the incidence of adhesion formation and death after abdominal irradiation in mice. Cancer Res 49: 169-73, 1989.
16. McBride WH, Dougherty GD, Wallis AE, Economou JS and Chiang CS: Interleukin-3 in gene therapy of cancer. Folia Biol (Praha) 40: 62-73, 1994.
17. McBride WH, Dougherty GJ. Dubinett SM and Economou JS: Interleukin-7-mediated cancer gene therapy. Gene Therapy, in press, 1995.
18. Dranoff G. Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D and Mulligan. RC: Vaccination with irradiated tumor cells engineered to secrete murine ganulocytemacrophage colony-stimulating factor stimulates potent, specific, and longlasting anti-tumor immunity. Proc Natl Acad Scil USA 90: 3539-3543, 1993.
19. Pardoll D: Immunotherapy with cytokine gene-transduced tumor cells: the next wave in gene therapy for cancer. Curr Opin Oncol 4: 1124-1129, 1992.
20. Abdel WZ. Osanto S. Darrow TL, Barber JR, Vervaert CE, Gangavalli R. McCallister TJ and Seigler HF: Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity. Cancer Gene Ther 1:171-179, 1994.
21. Cornetta K, Bcrebitsky D, Behnia M, Traycoff C, Srour EF and Sledge GW: A retroviral vector expressing human interferon gamma upregulates MHC antigen expression in human breast cancer and leukemia cell lines. Cancer Gene Ther 1. 91-8, 1994.
22. Kim HS, Kang CM, Findley H and Ragab AH: Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci USA 90: 2774-2778,1993.
23. Matory YL, Chen M, Dorfman DM, Williams A, Goedegebuure PS and Eberlein TJ: Antitumor activity of three mouse mammary cancer cell lines after interferon-gamma gene transfection. Surgery 118. 251-256, 1995.
24. Sharma S, Wang J, Huang M, Paul RW, Lee P, McBride WH, Economou JS, Roth MD, Kiertscher SM and Dubinett SM: Interleukin 7 gene transfer in non-small cell lung cancer decreases tumor proliferation, modifies cell surface molecule expression and enhances antitumor reactivity. In press. 1995.
25. Dubinett SM, Huang M, Dhanani S, Economou JS, Wang J, Lee P, Sharma S, Dougherty GJ and McBride WH: Down-regulation of murine fibrosarcoma transforming growth factor-beta 1 expression by interleukin 7. J Natl Cancer Inst 87: 593-597, 1995.
26. Dubinett SM, Huang M, Wang J, Berotza, T and Dhanani S: Downregulation of macrophage transforming growth factor-b messenger mRNA expression by IL-7. J Immunol 151. 6670-6680, 1993.
27. Pulaski BA, McAdam AJ, Hutter HK, Biggar S, Lord EM and Frelinger JG: Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dcpendent mechanism. Cancer Res 53: 2112-2117, 1993.
28. Howic S and McBride WH: Tumour specific T helper activity can be abrogated by two distinct suppressor cell mechanisms. Eur J Immunol 12: 671 -675, 1982.
29. McBride WH and Howie S: Paradoxical presence of T cell anergy during successful T cell-dependent tumour immunotherapy: characterization of a state of T cell 'amnaesia' following systemic administration of C. parvum. Clin Exp Immunol 57: 139-148, 1984.
30. McBride WH and Howie SE: Induction of tolerance to a murine fibrosarcoma in two zones of dosage-the involvement of suppressor cells. Br J Cancer 53: 707-711, 1986.
31. McBride WH and Dougherty GJ: Radiotherapy for gene that cause cancer. Nature Medicine 1: 1215-1217, 1995.
32. McBride WH, Economou JS, Kuber N, Hong JH, Chiang CS, Syljuasen R, Dougherty ST and Dougherty GJ: Modification of tumor microenvironment by cytokine gene transfer. Acta Oncol 34: 447-451, 1995.